Abstract
Outcomes of kidney transplantation, in terms of graft and patient survival, have improved over the past few decades, partly as a result of the introduction of new immunosuppressive drugs. Many immunosuppressive agents are associated with an increased risk of cardiovascular events and an increased risk of cancer, however, which can compromise patient survival. Cancer is more common among solid-organ transplant recipients than it is in the general population or in patients on dialysis. In fact, malignancy is the third most common cause of death in renal transplant recipients. Immunosuppressive treatments used in renal transplant recipients can cause malignancy by supporting oncogenesis caused by certain viruses or by impairing immune surveillance thereby enabling faster tumor growth. In this Review, we describe the epidemiological and clinical characteristics of common tumor types occurring after kidney transplantation, and the etiopathogenetic factors that lead to their appearance, with a particular focus on the relationship between immunosuppressive treatment and malignancy. Immunosuppressive drugs associated with an increased risk of malignancy after transplantation are also discussed, as are immunosuppressive drugs that seem to have antioncogenic properties.
Key Points
-
Malignancy is the third most common cause of death after renal transplantation
-
Common malignancies in renal transplant recipients include skin cancer, melanoma, Kaposi's sarcoma and post-transplantation lymphoproliferative disorders
-
Factors associated with the development of cancer in transplant recipients include carcinogenic factors, impaired immune surveillance owing to immunosuppression, a genetic predisposition to cancer and the presence of certain viral infections
-
Renal transplant recipients should be screened for cancer regularly after transplantation to enable early intervention when necessary
-
Immunosuppressive treatments in renal transplant recipients should be modulated to try and balance the risks of graft rejection and cancer development
-
Malignancies should be managed with specific therapies for the particular tumor type and with strategies such as immunosuppression reduction, immunosuppression withdrawal or conversion to alternative immunosuppressive regimens
Similar content being viewed by others
References
Schnuelle, P., Lorenz, D., Trede, M. & Van Der Woude, F. J. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J. Am. Soc. Nephrol. 9, 2135–2141 (1998).
Port, F. K., Wolfe, R. A., Mauger, E. A., Berling, D. P. & Jiang, K. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 270, 1339–1343 (1993).
Wolfe, R. A. et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N. Engl. J. Med. 341, 1725–1730 (1999).
Meier-Kriesche, H. U. et al. Survival improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients. J. Am. Soc. Nephrol. 12, 1293–1296 (2001).
Oniscu, G. C., Brown, H. & Forsythe, J. L. Impact of cadaveric renal transplantation on survival in patients listed for transplantation. J. Am. Soc. Nephrol. 16, 1859–1865 (2005).
Ojo, A. O. et al. Comparative mortality risks of chronic dialysis and cadaveric transplantation in black end-stage renal disease patients. Am. J. Kidney Dis. 24, 59–64 (1994).
Gill, J. S. et al. The impact of waiting time and comorbid conditions on the survival benefit of kidney transplantation. Kidney Int. 68, 2345–2351 (2005).
O'Grady, J. G., Burroughs, A., Hardy, P., Elbourne, D. & Truesdale, A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomized controlled trial. Lancet 360, 1119–1125 (2002).
Knight, S. R. et al. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation 87, 785–794 (2009).
Opelz, G. & Henderson, R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342, 1514–1516 (1993).
Howard, R. J. et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 73, 1923–1928 (2002).
Collins, A. J. et al. Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States. Am. J. Kidney Dis. 42 (Suppl. 5), S1–S230 (2003).
Briggs, J. D. Causes of death after renal transplantation. Nephrol. Dial. Transplant. 16, 1545–1549 (2001).
Wimmer, C. D. et al. The janus face of immunosuppression—de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int. 71, 1271–1278 (2007).
Penn, I. Malignant melanoma in organ allograft recipients. Transplantation 61, 274–278 (1996).
Birkeland, S. A., Lokkegaard, H. & Storm, H. H. Cancer risk in patients on dialysis and after renal transplantation. Lancet 355, 1886–1887 (2000).
Adami, J. et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br. J. Cancer 89, 1221–1227 (2003).
Kasiske, B. L., Snyder, J. J., Gilbertson, D. T. & Wang, C. Cancer after kidney transplantation in the United States. Am. J. Transplant. 4, 905–913 (2004).
Grulich, A. E., van Leeuwen, M. T., Falster, M. O. & Vajdic, C. M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370, 59–67 (2007).
Visonneau, S., Cesano, A., Torosian, M. H., Miller, E. J. & Santoli, D. Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice. Am. J. Pathol. 152, 1299–1311 (1998).
Stewart, T., Tsai, S. C., Grayson, H., Henderson, R. & Opelz, G. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 346, 796–798 (1995).
Mihalov, M. L., Gattuso. P., Abraham, K., Holmes, E. W. & Reddy, V. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin. Transplant. 10, 248–255 (1996).
Jensen, P. et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J. Am. Acad. Dermatol. 40, 177–186 (1999).
Fortina, A. B. et al. Skin cancer in heart transplant recipients: frequency and risk factor analysis. J. Heart Lung Transplant. 19, 249–255 (2000).
Penn, I. Incidence and treatment of neoplasia after transplantation. J. Heart Lung Transplant. 12, S328–S336 (1993).
Kiberd, B. A., Rose, C. & Gill, J. S. Cancer mortality in kidney transplant recipients. Am. J. Transplant. 9, 1868–1875 (2009).
Pedotti, P., Cardillo, M., Rossini, G. & Arcuri, V. Incidence of cancer after kidney transplant: results from the North Italy transplant program. Transplantation 76, 1448–1451 (2003).
Miao, Y. et al. De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation 87, 1347–1359 (2009).
de Fijter, J. W. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. Nephrol. Dial. Transplant. 22 (Suppl. 1), i23–i26 (2007).
Webb, M. C., Compton, F., Andrews, P. A. & Koffman, C. G. Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre. Transplant. Proc. 29, 828–830 (1997).
Euvrard, S. et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J. Am. Acad. Dermatol. 33, 222–229 (1995).
Christenson, L. J. et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 294, 681–690 (2005).
Urwin, H. R. et al. Predicting risk of nonmelanoma skin cancer and premalignant skin lesions in renal transplant recipients. Transplantation 87, 1667–1671 (2009).
Vajdic, C. M. et al. Cutaneous melanoma is related to immune suppression in kidney transplant recipients. Cancer Epidemiol. Biomarkers Prev. 18, 2297–2303 (2009).
Dapprich, D. C. et al. Outcomes of melanoma in recipients of solid organ transplant. J. Am. Acad. Dermatol. 59, 405–417 (2008).
Matin, R. N. et al. Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases. Am. J. Transplant. 8, 1891–1900 (2008).
Campistol, J. M. & Schena, F. P. Kaposi's sarcoma in renal transplant recipients—the impact of proliferation signal inhibitors. Nephrol. Dial. Transplant. 22 (Suppl. 1), i17–i22 (2007).
Moosa, M. R. Racial and ethnic variations in incidence and pattern of malignancies after kidney transplantation. Medicine 84, 12–22 (2005).
Francès, C. et al. The impact of preexisting or acquired Kaposi sarcoma herpesvirus infection in kidney transplant recipients on morbidity and survival. Am. J. Transplant. 9, 2580–2586 (2009).
Pascual, J. Post-transplant lymphoproliferative disorder—the potential of proliferation signal inhibitors. Nephrol. Dial. Transplant. 22 (Suppl. 1), i27–i35 (2007).
Caillard, S., Agodoa, L. Y., Bohen, E. M. & Abbott, K. C. Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation 81, 888–895 (2006).
Koukourgianni, F. et al. Malignancy incidence after renal transplantation in children: a 20-year single centre experience. Nephrol. Dial. Transplant. 25, 611–616 (2010).
Berg, D. & Otley, C. C. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. Am. Acad. Dermatol. 47, 1–17 (2002).
Penn, I. & First, M. R. Merkel's cell carcinoma in organ recipients: report of 41 cases. Transplantation 68, 1717–1721 (1999).
Vajdic, C. M. et al. Increased incidence of squamous cell carcinoma of eye after kidney transplantation. J. Natl Cancer Inst. 99, 1340–1342 (2007).
Penn, I. Cancers complicating organ transplantation. N. Engl. J. Med. 323, 1767–1769 (1990).
Penn, I. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 58, 611–616 (1986).
Anyanwu, A. C. et al. Primary lung carcinoma after heart or lung transplantation: management and outcome. J. Thorac. Cardiovasc. Surg. 124, 1190–1197 (2002).
Rinaldi, M. et al. Neoplastic disease after heart transplantation: single center experience. Eur. J. Cardiothorac. Surg. 19, 696–701 (2001).
Goldstein, D. J. et al. Carcinoma of the lung after heart transplantation. Transplantation 62, 772–775 (1996).
Buell, J. F. et al. Donor transmitted malignancies. Ann. Transplant. 9, 53–56 (2004).
Kauffman, H. M., McBride, M. A. & Delmonico, F. L. First report of the United Network for Organ Sharing Transplant Tumor Registry: Donors with a history of cancer. Transplantation 70, 1747–1751 (2000).
Morath, C. et al. Malignancy in renal transplantation. J. Am. Soc. Nephrol. 15, 1582–1588 (2004).
Ramsay, H. M., Fryer, A. A., Reece, S., Smith, A. G. & Harden, P. N. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am. J. Kidney Dis. 36, 167–176 (2000).
Fortina, A. B. et al. Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients. Arch. Dermatol. 140, 1079–1085 (2004).
Opelz, G. & Döhler, B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am. J. Transplant. 4, 222–230 (2004).
Dantal, J. et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomized comparison of two cyclosporin regimens. Lancet 351, 623–628 (1998).
Melosky, B. et al. Lymphoproliferative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression. J. Am. Soc. Nephrol. 212 (Suppl.), S290–S294 (1992).
Caforio, A. L. et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 102 (Suppl. 3), III222–III227 (2000).
Kirk, A. D. et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am. J. Transplant. 7, 2619–2625 (2007).
Hojo, M. et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397, 530–534 (1999).
Maluccio, M. et al. Tacrolimus enhances transforming growth factor-β1 expression and promotes tumor progression. Transplantation 76, 597–602 (2003).
Harwood, C. A. et al. PTCH mutations in basal cell carcinomas from azathioprine-treated organ transplant recipients. Br. J. Cancer 99, 1276–1284 (2008).
Guba, M. et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8, 128–135 (2002).
Luan, F. L. et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int. 63, 917–926 (2003).
Guba, M., Graeb, C., Jauch, K. W. & Geissler, E. K. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 77, 1777–1782 (2004).
Campistol, J. M. et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J. Am. Soc. Nephrol. 1, 581–589 (2006).
Mathew, T., Kreis, H. & Friend, P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin. Transplant. 18, 446–449 (2004).
Euvrard, S., Ulrich, C. & Lefrancois, N. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol. Surg. 30, 628–633 (2004).
Kahan, B. D. et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 80, 749–758 (2005).
Campistol, J. M., Gutierrez-Dalmau, A. & Torregrosa, J. V. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 77, 760–762 (2004).
Stallone, G. et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N. Engl. J. Med. 352, 1317–1323 (2005).
Kauffman, H. M., Cherikh, W. S., Cheng, Y., Hanto, D. W. & Kahan, B. D. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80, 883–889 (2005).
Ramsay, H. M. et al. Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. J. Am. Acad. Dermatol. 49, 397–406 (2003).
Dreno, B. Skin cancers after transplantation. Nephrol. Dial. Transplant. 8, 1052–1058 (2003).
Chu, P. G. et al. Epstein–Barr virus (EBV) nuclear antigen (EBNA)-4 mutation in EBV-associated malignancies in three different populations. Am. J. Pathol. 155, 941–947 (1999).
van Leeuwen, M. T. et al. Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood 114, 630–637 (2009).
Liebowitz, D. Epstein–Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N. Engl. J. Med. 338, 1413–1421 (1998).
Izumi, K. M., Kaye, K. M. & Kieff, E. D. The Epstein–Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc. Natl Acad. Sci. USA 94, 1447–1452 (1997).
Song, Y. J., Izumi, K. M., Shinners, N. P., Gewurz, B. E. & Kieff, E. IRF7 activation by Epstein–Barr virus latent membrane protein 1 requires localization at activation sites and TRAF6, but not TRAF2 or TRAF3. Proc. Natl Acad. Sci. USA 105, 18448–18453 (2008).
Mosialos, G. Cytokine signaling and Epstein–Barr virus-mediated cell transformation. Cytokine Growth Factor Rev. 12, 259–270 (2001).
Caillard, S., Dharnidharka, V., Agodoa, L., Bohen, E. & Abbott, K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 80, 1233–1243 (2005).
Robson, R., Cecka, J. M., Opelz, G., Budde, M. & Sacks, S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am. J. Transplant. 5, 2954–2960 (2005).
Pirsch, J. D. Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U. S. multicenter FK506 Kidney Transplant Study Group. Transplantation 68, 1203–1205 (1999).
Birkeland, S. A. & Hamilton-Dutoit, S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation 76, 984–988 (2003).
Majewski, M. et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein–Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc. Natl Acad. Sci. USA 97, 4285–4290 (2000).
Majewski, M. et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 75, 1710–1717 (2003).
Nepomuceno, R. R. et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein–Barr virus B-cell lymphomas. Cancer Res. 63, 4472–4480 (2003).
Akula, S. M., Pramod, N. P., Wang, F. Z. & Chandran, B. Integrin α3β1 (CD 49c/29) is a cellular receptor for Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) entry into the target cells. Cell 108, 407–419 (2002).
Paulose-Murphy, M. et al. Transcription program of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus). J. Virol. 75, 4843–4853 (2001).
Mercader, M. et al. Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells. Am. J. Pathol. 156, 1961–1971 (2000).
Chang, J., Renne, R., Dittmer, D. & Ganem, D. Inflammatory cytokines and the reactivation of Kaposi's sarcoma-associated herpesvirus lytic replication. Virology 266, 17–25 (2000).
Davis, D. A. et al. Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood 97, 3244–3250 (2001).
Weber, K. S. et al. Selective recruitment of Th2-type cells and evasion from a cytotoxic immune response mediated by viral macrophage inhibitory protein-II. Eur. J. Immunol. 31, 2458–2466 (2001).
Lubyova, B. & Pitha, P. M. Characterization of a novel human herpesvirus 8-encoded protein, vIRF-3, that shows homology to viral and cellular interferon regulatory factors. J. Virol. 74, 8194–8201 (2000).
Brander, C. et al. Impaired CTL recognition of cells latently infected with Kaposi's sarcoma-associated herpes virus. J. Immunol. 165, 2077–2083 (2000).
Ishido, S., Wang, C., Lee, B. S., Cohen, G. B. & Jung, J. U. Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J. Virol. 74, 5300–5309 (2000).
Coscoy, L. & Ganem, D. A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation. J. Clin. Invest. 107, 1599–1606 (2001).
Bertin, J. et al. Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. Proc. Natl Acad. Sci. USA 94, 1172–1176 (1997).
Lundquist, A. et al. Kaposi sarcoma-associated viral cyclin K overrides cell growth inhibition mediated by oncostatin M through STAT3 inhibition. Blood 101, 4070–4077 (2003).
Flore, O. et al. Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus. Nature 394, 588–592 (1998).
Pati, S. et al. Activation of NF-κB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi's sarcoma pathogenesis. J. Virol. 75, 8660–8673 (2001).
Bais, C. et al. G-protein coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391, 86–89 (1998).
Wang, H. W. et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat. Genet. 36, 687–693 (2004).
Qunibi, W. et al. Serologic association of human herpesvirus eight with posttransplant Kaposi's sarcoma in Saudi Arabia. Transplantation 65, 583–585 (1998).
Frances, C. et al. Outcome of kidney transplant recipients with previous human herpesvirus-8 infection. Transplantation 69, 1776–1779 (2000).
Diociaiuti, A. et al. HHV8 in renal transplant recipients. Transpl. Int. 13 (Suppl. 1), S410–S412 (2000).
Cattani, P. et al. Kaposi's sarcoma associated with previous human herpesvirus 8 infection in kidney transplant recipients. J. Clin. Microbiol. 39, 506–508 (2001).
Regamey, N. et al. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N. Engl. J. Med. 339, 1358–1363 (1998).
Barozzi, P. et al. Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat. Med. 9, 554–561 (2003).
Barozzi, P. et al. Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma. Transplantation 86, 738–744 (2008).
Maisonneuve, P. et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354, 93–99 (1999).
Gulanikar, A. C., Daily, P. P., Kilambi, N. K., Hamrick-Turner, J. E. & Butkus, D. E. Prospective pretransplant ultrasound screening in 206 patients for acquired renal cysts and renal cell carcinoma. Transplantation 66, 1669–1672 (1998).
Kasiske, B. L. et al. The evaluation of renal transplant candidates: clinical practice guidelines. Am. J. Transplant. 1 (Suppl. 2), 3–95 (2001).
Kasiske, B. L. et al. The evaluation of renal transplant candidates: clinical practice guidelines. J. Am. Soc. Nephrol. 6, 1–34 (1995).
Knoll, G. et al. Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation. CMAJ 173, S1–S25 (2005).
Penn, I. The effect of immunosuppression on pre-existing cancers. Transplantation 55, 742–747 (1993).
Ajithkumar, T. V., Parkinson, C. A., Butler, A. & Hatcher, H. M. Management of solid tumours in organ-transplant recipients. Lancet Oncol. 8, 921–932 (2007).
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant. (Suppl. 3), S1–S155 (2009).
Fuente, M. J. et al. A prospective study of the incidence of skin cancer and its risk factors in a Spanish Mediterranean population of kidney transplant recipients. Br. J. Dermatol. 149, 1221–1226 (2003).
Webster, A. C., Wong, G., Craig, J. C. & Chapman, J. R. Managing cancer risk and decision making after kidney transplantation. Am. J. Transplant. 8, 2185–2191 (2008).
Scott, S. D. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract. 6, 195–197 (2001).
Verschuuren, E. A. et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation 73, 100–104 (2002).
Blaes, A. H., Peterson, B. A., Bartlett, N., Dunn, D. L. & Morrison, V. A. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation. Cancer 104, 1661–1667 (2005).
Choquet, S. et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 107, 3053–3057 (2006).
EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol. Dial. Transplant. 17 (Suppl. 4), 31–33 (2002).
Sato, T. et al. Monitoring of Epstein–Barr virus load and antibody in pediatric renal transplant patients. Pediatr. Int. 50, 454–458 (2008).
Vo, A. A. et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 89, 1095–1102 (2010).
van den Hoogen, M. W. & Hilbrands, L. B. More on B-cell-depleting induction therapy and acute cellular rejection. N. Engl. J. Med. 361, 1215 (2009).
Durrbach, A. et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am. J. Transplant. 10, 547–557 (2010).
Duman, S. et al. Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression. Nephrol. Dial. Transplant. 17, 892–896 (2002).
Campistol, J. M. Minimizing the risk of posttransplant malignancy. Transplantation 87 (Suppl.), S19–S22 (2009).
Mohsin, N. et al. Complete regression of visceral Kaposi's sarcoma after conversion to sirolimus. Exp. Clin. Transplant. 3, 366–369 (2005).
Monaco, A. P. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 87, 157–163 (2009).
Gomez-Camarero, J. et al. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation 84, 786–791 (2007).
Acknowledgements
Laurie Barclay, freelance writer and reviewer, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the MedscapeCME-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Contributions
I. Rama and J. M. Grinyó both contributed to researching data for article, discussing the content, writing the article, and reviewing and editing the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Rama, I., Grinyó, J. Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol 6, 511–519 (2010). https://doi.org/10.1038/nrneph.2010.102
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2010.102
- Springer Nature Limited
This article is cited by
-
Ipsilateral synchronous papillary renal neoplasm with reverse polarity and urothelial carcinoma in a renal transplant recipient: a rare case report with molecular analysis and literature review
Diagnostic Pathology (2023)
-
IL-37 overexpression promotes endometrial regenerative cell-mediated inhibition of cardiac allograft rejection
Stem Cell Research & Therapy (2022)
-
Laryngeal Dysplasia: To Biopsy or Not?
Indian Journal of Otolaryngology and Head & Neck Surgery (2022)
-
The effect of subsequent immunosuppressant use in organ-transplanted patients on prostate cancer incidence: a retrospective analysis using the Korean National Health Insurance Database
BMC Urology (2021)
-
Long-term Survival After Nephron-Sparing Surgery for Kidney Allograft Tumors: Case Reports from a Single Transplant Center
SN Comprehensive Clinical Medicine (2021)